Table 4.
Baseline characteristics of the latent classes
| ERAN | BSRBR TNF inhibitor cohort | BSRBR control cohort | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concordant/Discordant | Con | Con | Con | Dis | Dis | Heterogeneity | Con | Con | Dis | Dis | Heterogeneity | Con | Con | Dis | Dis | Heterogeneity |
| Descriptor | Mild | Moderate | Severe | Better patient-reported | Worse patient-reported | Moderate | Severe | Better patient-reported | Worse patient-reported | Mild | Moderate | Better patient-reported | Worse patient-reported | |||
| Age | 58 (13) | 56 (14) | 55 (14) | 58 (13) | 57 (13) | 56 (13) | 56 (12) | 57 (14) | 56 (12) | * | 60 (12) | 61 912) | 59 (12) | 59 (12) | * | |
| Female | 60% | 68% | 65% | 66% | 81% | * | 72% | 79% | 75% | 77% | * | 69% | 73% | 71% | 77% | * |
| DAS28 | 3.2 (1.1) | 4.3 (1.0) | 6.9 (0.8) | 6.0 (0.7) | 5.7 (0.8) | * | 5.6 (0.9) | 7.5 (0.7) | 7.0 (0.7) | 6.2 (0.7) | * | 4.1 (1.1) | 4.9 (1.0) | 7.0 (0.8) | 5.7 (1.0) | * |
| HAQ | 0.4 (0.5) | 1.1 (0.6) | 1.8 (0.6) | 1.3 (0.6) | 1.8 (0.7) | * | 2.0 (0.6) | 2.0 (0.6) | 2.1 (0.6) | 2.0 (0.6) | 0.7 (0.6) | 1.5 (0.6) | 1.8 (0.6) | 2.1 (0.5) | * | |
Clinical variables not used in the latent class analysis are compared between identified latent classes. Mean (SD) or percentage data are presented
Abbreviations: BSRBR, British Society for Rheumatology Biologics Registers, DAS28 28-joint Disease Activity Score, ERAN Early Rheumatoid Arthritis Network, HAQ Health Assessment Questionnaire, TNF Tumour necrosis factor, Dis Discordant, Con Concordant
*p < 0.05 from one-way analysis of variance for heterogeneity between latent classes within one cohort